ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
ImmunityBio, Inc. (IBRX)
Company Research
Source: Business Wire
First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen to be evaluated in indolent non-Hodgkin lymphoma (iNHL), including Waldenström’s MacroglobulinemiaResQ215B builds on a Phase 1 study that demonstrated that CAR-NK cell therapy plus rituximab administered without chemotherapy or ANKTIVA in iNHL, including Waldenström’s Macroglobulinemia, resulted in durable complete responsesCD19 t-haNK, an off-the-shelf CAR-NK cell therapy, is designed to induce direct tumor cell killing and enhance antibody-dependent cellular cytotoxicity (ADCC) when combined with anti-CD20 antibody rituximabThe addition of ANKTIVA aims to further enhance NK and T-cell activity and potentially overcome tumor resistance to rituximab, thereby improving the depth and durability of responses in indolent lymphomas CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXGlobeNewswire
- ImmunityBio (NASDAQ:IBRX) had its price target raised by analysts at HC Wainwright from $8.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 1/26/26 - Form 8-K
- 1/21/26 - Form 4
- 1/21/26 - Form 4
- IBRX's page on the SEC website